Evidence
Nutrients. 2023 Apr 25;15(9):2068. doi: 10.3390/nu15092068.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition characterized by lipid accumulation in hepatocytes with low alcohol consumption. The development of sterile inflammation, which occurs in response to a range of cellular stressors or injuries, has been identified as a major contributor to the pathogenesis of NAFLD. Recent studies of the pathogenesis of NAFLD reported the newly developed roles of damage-associated molecular patterns (DAMPs). These molecules activate pattern recognition receptors (PRRs), which are placed in the infiltrated neutrophils, dendritic cells, monocytes, or Kupffer cells. DAMPs cause the activation of PRRs, which triggers a number of immunological responses, including the generation of cytokines that promote inflammation and the localization of immune cells to the site of the damage. This review provides a comprehensive overview of the impact of DAMPs and PRRs on the development of NAFLD.
PMID:37432213 | DOI:10.3390/nu15092068
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Search [Andisearch.com]
AI Q/A [Aikko.com]
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
🌐 90 Days
VR Related Evidence Matrix
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Innate immune activation in neurodegenerative diseases
- Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Bacteroides and NAFLD: pathophysiology and therapy
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- (+)-Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease
- Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Interleukins in liver disease treatment
- Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis
- Significant association of elevated serum galectin-9 levels with the development of non-alcoholic fatty liver disease in patients with rheumatoid arthritis
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- BNIP3 in hypoxia-induced mitophagy: novel insights and promising target for non-alcoholic fatty liver disease
- Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review)
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- A bibliometric analysis of macrophages associated with non-alcoholic fatty liver disease research from 2005 to 2023
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice
- Natural compounds proposed for the management of non-alcoholic fatty liver disease
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- A functional genomic framework to elucidate novel causal non-alcoholic fatty liver disease genes
- Chronic exposure to 3,6-dichlorocarbazole exacerbates non-alcoholic fatty liver disease in zebrafish by disrupting lipid metabolism and inducing special lipid biomarker accumulation
- Unveiling the mitophagy puzzle in non-alcoholic fatty liver disease (NAFLD): Six hub genes for early diagnosis and immune modulatory roles
- Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
- Chronic exposure to parabens promotes non-alcoholic fatty liver disease in association with the changes of the gut microbiota and lipid metabolism
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Pharmacology of bioactive compounds from plant extracts for improving non-alcoholic fatty liver disease through endoplasmic reticulum stress modulation: A comprehensive review
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- The double roles of T cell-mediated immune response in the progression of MASLD
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Costunolide attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease
- The effects of replacing ghee with rapeseed oil on liver steatosis and enzymes, lipid profile, insulin resistance, and anthropometric measurements in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- Dietary pattern associated with non-alcoholic fatty liver disease (NAFLD) in non-diabetic adult patients: A case control study
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Fructose regulates the pentose phosphate pathway and induces an inflammatory and resolution phenotype in Kupffer cells
- Inflammatory liver diseases and susceptibility to sepsis
- The role of gut microbiota in the occurrence and progression of non-alcoholic fatty liver disease
- Beneficial Effects of Dietary Flaxseed on Non-Alcoholic Fatty Liver Disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
Evidence Blueprint
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
Save Evidence Blueprint
Save as PDF
Innate Immune System in the Pathogenesis of Non-Alcoholic Fatty Liver Disease
🌐 365 Days
VR Related Evidence Matrix
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- From complement to complosome in non-alcoholic fatty liver disease: When location matters
- Major roles of kupffer cells and macrophages in NAFLD development
- Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
- Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg
- Gut microbe and hepatic macrophage polarization in non-alcoholic fatty liver disease
- Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
- Innate immune activation in neurodegenerative diseases
- The hepatitis B virus promotes the progression of non-alcoholic fatty liver disease through incomplete autophagy
- Neutrophils: tissue and circulating signatures of pediatric non-alcoholic fatty liver disease
- The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
- Ufmylation on UFBP1 alleviates non-alcoholic fatty liver disease by modulating hepatic endoplasmic reticulum stress
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Galectin-12 modulates Kupffer cell polarization to alter the progression of non-alcoholic fatty liver disease
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- Long-term and liver-selected ginsenoside C-K nanoparticles retard NAFLD progression by restoring lipid homeostasis
- Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
- Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease
- Macrophages and the development and progression of non-alcoholic fatty liver disease
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF pathways
- Histological features of non-alcoholic fatty liver disease revealed in response to mixed vehicle emission exposure and consumption of a high-fat diet in wildtype C57Bl/6 male mice
- MicroRNA-574-5p targeting HOXC6 expression inhibits the hepatocyte lipid uptake to alleviate non-alcoholic fatty liver disease
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells
- Cholesterol Exacerbates the Pathophysiology of Non-Alcoholic Steatohepatitis by Upregulating Hypoxia-Inducible Factor 1 and Modulating Microcirculatory Dysfunction
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease
- Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Doxorubicin Attenuates Free Fatty Acid-Induced Lipid Accumulation via Stimulation of p53 in HepG2 Cells
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Interleukin-1ß Attenuates Expression of Augmenter of Liver Regeneration (ALR) by Regulating HNF4α Independent of c-Jun
- Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation
- Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives
- Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease
- Targeting Extracellular RNA Mitigates Hepatic Lipotoxicity and Liver Injury in NASH
- Blood-brain crosstalk: the roles of neutrophils, platelets, and neutrophil extracellular traps in neuropathologies
- Bempedoic acid unveils therapeutic potential in non-alcoholic fatty liver disease: suppression of the hepatic PXR-SLC13A5/ACLY signaling axis
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- Peripheral and central macrophages in obesity
- Myokines: Crosstalk and Consequences on Liver Physiopathology
- The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay
- High-cholesterol diet in combination with hydroxypropyl-beta-cyclodextrin induces NASH-like disorders in the liver of rats
- Insights of mitochondrial involvement in alcoholic fatty liver disease
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Effects of riboflavin deficiency and high dietary fat on hepatic lipid accumulation: a synergetic action in the development of non-alcoholic fatty liver disease
- HMGA2 knockdown alleviates the progression of nonalcoholic fatty liver disease (NAFLD) by downregulating SNAI2 expression
- Pharmacological inhibition of DNMT1 restores macrophage autophagy and M2 polarization in western diet-induced Nonalcoholic fatty liver disease
- Bacteroides and NAFLD: pathophysiology and therapy
- Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice
- Identification and validation of disulfidptosis-associated molecular clusters in non-alcoholic fatty liver disease
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- The Association between Liver Enzymes and Mortality Stratified by Non-Alcoholic Fatty Liver Disease: An Analysis of NHANES III
- A high-trans fat, high-carbohydrate, high-cholesterol, high-cholate diet-induced nonalcoholic steatohepatitis mouse model and its hepatic immune response
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota